Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. It specializes in the development of vaccines using computationally designed virus-like particles (VLPs). The company's primary focus is on creating safe and effective vaccines to address significant unmet medical needs in the realm of infectious diseases, particularly life-threatening respiratory illnesses. One of its key vaccine candidates is IVX-121, aimed at protecting older adults from respiratory syncytial virus (RSV) disease. Icosavax leverages exclusive technology licensed from the Institute for Protein Design at the University of Washington to advance its innovative vaccine solutions.
Natron Energy, Inc. is an energy storage company specializing in the development of sodium-ion batteries designed for industrial applications. Founded in 2012 and based in Santa Clara, California, the company focuses on delivering high power, long cycle life, and cost-effective battery solutions. Its products utilize a unique Prussian blue chemistry, making them suitable for a range of applications, including uninterruptible power supplies, lift trucks, renewable energy smoothing, smart grids, and electric vehicle fast charging. Natron Energy aims to provide efficient energy storage systems that can be economically produced using readily available materials and existing manufacturing processes, thus enhancing the performance and lifespan of batteries while maintaining low operating costs.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Arctos Medical
Seed Round in 2019
Arctos Medical is a spin-off company from the University of Bern and has developed a revolutionary gene therapy that does not correct rare genetic eye diseases but much more common cases of blindness.
Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. It specializes in the development of vaccines using computationally designed virus-like particles (VLPs). The company's primary focus is on creating safe and effective vaccines to address significant unmet medical needs in the realm of infectious diseases, particularly life-threatening respiratory illnesses. One of its key vaccine candidates is IVX-121, aimed at protecting older adults from respiratory syncytial virus (RSV) disease. Icosavax leverages exclusive technology licensed from the Institute for Protein Design at the University of Washington to advance its innovative vaccine solutions.
Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing bifunctional antibody therapies aimed at treating hematologic malignancies. Founded in 2012 and based in South San Francisco, California, the company utilizes its proprietary ReSTORE platform to create dual-action biologics that enhance the patient's immune response against cancer. These therapies are designed to relieve immune suppression while activating T cells, thereby promoting the destruction of tumor cells and their precursors. The platform emphasizes avidity, target selectivity, and safety, and can be engineered to include additional functionalities for targeting solid tumors. As a subsidiary of Affimed N.V., Amphivena Therapeutics aims to provide innovative treatment options for patients facing blood cancers.
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
Serotiny, Inc. is a biotechnology company based in San Francisco, California, that specializes in the design and development of multi-domain proteins and therapies aimed at treating cancers and genetic disorders. Founded in 2014, Serotiny utilizes a combination of mammalian synthetic biology and informatics to achieve rational protein design. The company collaborates with leaders in the life sciences to create innovative therapies and tools, tailoring its protein designs to meet specific therapeutic needs.
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
H55 S.A. manufactures electric propulsion system and battery management solutions for aircrafts. It offers software and hardware solutions for integrating propeller, transmission systems, electric motors and controllers, energy storage, and pilot interface. The company was founded in 2015 and is based in Sion, Switzerland.
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.
Inscripta, Inc. is a gene editing technology company focused on developing advanced CRISPR enzymes, specifically MADzymes, for precision gene editing. Founded in 2015 and headquartered in Boulder, Colorado, with additional offices in Pleasanton and San Diego, Inscripta aims to revolutionize genome engineering through its innovative benchtop platform. This platform integrates an instrument, consumables, software, and assays to facilitate fully automated and scalable editing of single cells, enabling researchers to conduct massively parallel experiments with unprecedented efficiency. By offering tools that simplify the editing process and making its MAD7 CRISPR nuclease available for research, Inscripta seeks to empower scientists in overcoming existing technical and licensing barriers, fostering a new era of biological discovery.
Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.
Emulate, Inc. specializes in developing organs-on-chips technology that emulates human biology to better understand the effects of diseases, medications, and environmental factors on human health. The company offers organ-chips that replicate the functions of various organs, including the lung, intestine, liver, and skin, and can simulate both normal and disease states. Emulate’s platform aims to provide more accurate predictions of human responses compared to traditional experimental methods, such as cell cultures or animal testing. The company serves a diverse clientele that includes biotechnology and pharmaceutical firms, consumer health and cosmetics companies, government agencies, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. It has shifted its focus towards advancing product innovation and safety across multiple sectors, including drug development and personalized medicine.
SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.
As of January 8, 2019, Pulse Therapeutics, Inc. was acquired by Ichor Vascular, Inc. Pulse Therapeutics, Inc., a medical technology company, develops magnetically-enhanced diffusion (MED) system for the treatment of stroke, heart, and other diseases. Its MED system is used to harness magnet-based technology to dissolve blood clots faster than current modalities. The company also provides MED MicroBeads that are designed to convey physician-selected agents faster to the blood clot; intravenously administered after thrombolysis therapy is initiated; and mechanical adjunct to standard of care IV thrombolysis. In addition, it offers touch screen operated MED Workstation. Pulse Therapeutics, Inc. was incorporated in 2008 and is based in St. Louis, Missouri.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
Crocus Technology International Corp. specializes in developing and supplying magnetic sensors and embedded memory solutions based on its patented magnetic logic unit technology. The company provides a range of magnetic sensor products, which include various architectures suitable for challenging environments, such as oil drilling, fluid level measurements, and solar energy applications. Its offerings cater to diverse sectors, including industrial, automotive, consumer electronics, and the Internet of Things. Additionally, Crocus Technology delivers magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries, addressing needs in telecommunications, networking, storage, computing, and handheld devices. Established in 2014, the company is headquartered in Santa Clara, California, with an additional office in Grenoble, France, and distributes its products through a network of sales distributors both domestically and internationally.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.
Private Equity Round in 2014
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
Emulate, Inc. specializes in developing organs-on-chips technology that emulates human biology to better understand the effects of diseases, medications, and environmental factors on human health. The company offers organ-chips that replicate the functions of various organs, including the lung, intestine, liver, and skin, and can simulate both normal and disease states. Emulate’s platform aims to provide more accurate predictions of human responses compared to traditional experimental methods, such as cell cultures or animal testing. The company serves a diverse clientele that includes biotechnology and pharmaceutical firms, consumer health and cosmetics companies, government agencies, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. It has shifted its focus towards advancing product innovation and safety across multiple sectors, including drug development and personalized medicine.
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.
View, Inc. specializes in designing and manufacturing glass systems for various sectors, including workplace, healthcare, education, and hospitality. Founded in 2006 and headquartered in Milpitas, California, with manufacturing facilities in Olive Branch, Mississippi, the company focuses on enhancing natural light in buildings through its innovative smart window technology. View's products, known for their energy efficiency and positive impact on human health and productivity, utilize artificial intelligence to automatically adjust to sunlight, optimizing light access while minimizing energy consumption. The company markets its solutions through direct sales and representatives both domestically and internationally, positioning itself as a leader in the smart windows industry.
Crocus Technology International Corp. specializes in developing and supplying magnetic sensors and embedded memory solutions based on its patented magnetic logic unit technology. The company provides a range of magnetic sensor products, which include various architectures suitable for challenging environments, such as oil drilling, fluid level measurements, and solar energy applications. Its offerings cater to diverse sectors, including industrial, automotive, consumer electronics, and the Internet of Things. Additionally, Crocus Technology delivers magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries, addressing needs in telecommunications, networking, storage, computing, and handheld devices. Established in 2014, the company is headquartered in Santa Clara, California, with an additional office in Grenoble, France, and distributes its products through a network of sales distributors both domestically and internationally.
View, Inc. specializes in designing and manufacturing glass systems for various sectors, including workplace, healthcare, education, and hospitality. Founded in 2006 and headquartered in Milpitas, California, with manufacturing facilities in Olive Branch, Mississippi, the company focuses on enhancing natural light in buildings through its innovative smart window technology. View's products, known for their energy efficiency and positive impact on human health and productivity, utilize artificial intelligence to automatically adjust to sunlight, optimizing light access while minimizing energy consumption. The company markets its solutions through direct sales and representatives both domestically and internationally, positioning itself as a leader in the smart windows industry.
Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.
View, Inc. specializes in designing and manufacturing glass systems for various sectors, including workplace, healthcare, education, and hospitality. Founded in 2006 and headquartered in Milpitas, California, with manufacturing facilities in Olive Branch, Mississippi, the company focuses on enhancing natural light in buildings through its innovative smart window technology. View's products, known for their energy efficiency and positive impact on human health and productivity, utilize artificial intelligence to automatically adjust to sunlight, optimizing light access while minimizing energy consumption. The company markets its solutions through direct sales and representatives both domestically and internationally, positioning itself as a leader in the smart windows industry.
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.
Crocus Technology International Corp. specializes in developing and supplying magnetic sensors and embedded memory solutions based on its patented magnetic logic unit technology. The company provides a range of magnetic sensor products, which include various architectures suitable for challenging environments, such as oil drilling, fluid level measurements, and solar energy applications. Its offerings cater to diverse sectors, including industrial, automotive, consumer electronics, and the Internet of Things. Additionally, Crocus Technology delivers magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries, addressing needs in telecommunications, networking, storage, computing, and handheld devices. Established in 2014, the company is headquartered in Santa Clara, California, with an additional office in Grenoble, France, and distributes its products through a network of sales distributors both domestically and internationally.
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
SBA Materials, Inc. engages in the development and commercialization of advanced electronic materials for back-end of line and packaging applications for semiconductor manufacturing. The company focuses on commercializing low-k dielectric materials for interlayer dielectric application to address the needs of the semiconductor manufacturing industry. Its products include uLK22, uLK1X, and optical films, as well as nano-porous/meso-porous materials. The company offers materials to address the unmet needs of electronic device manufacturers. SBA Materials, Inc. was founded in 2001 and is based in Albuquerque, New Mexico.
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
Crocus Technology International Corp. specializes in developing and supplying magnetic sensors and embedded memory solutions based on its patented magnetic logic unit technology. The company provides a range of magnetic sensor products, which include various architectures suitable for challenging environments, such as oil drilling, fluid level measurements, and solar energy applications. Its offerings cater to diverse sectors, including industrial, automotive, consumer electronics, and the Internet of Things. Additionally, Crocus Technology delivers magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries, addressing needs in telecommunications, networking, storage, computing, and handheld devices. Established in 2014, the company is headquartered in Santa Clara, California, with an additional office in Grenoble, France, and distributes its products through a network of sales distributors both domestically and internationally.
Xtellus, Inc. provides reconfigurable optical add/drop multiplexers (ROADM) technology and dynamic optical modules for agile optical networking systems. It offers wavelength selective switches, wavelength blockers, edge wavelength selective switches, and ROADM modules with integrated power monitoring and muxes/demuxes; and liquid crystal optical processors. Xtellus, Inc. was founded in 2000 and is based in Morris Plains, New Jersey. It has manufacturing and development facilities in Israel and South Korea. The company also has a research and development facility in Jerusalem, Israel. As of December 17, 2009, Xtellus, Inc. operates as a subsidiary of Oclaro, Inc.
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.